Clinical Trials Logo

Motor Neuron Disease clinical trials

View clinical trials related to Motor Neuron Disease.

Filter by:

NCT ID: NCT04326283 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

Start date: April 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.

NCT ID: NCT04288856 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

Start date: April 28, 2020
Phase: Phase 1
Study type: Interventional

The primary objective is to evaluate the long-term safety and tolerability of BIIB078 in participants with chromosome 9 open reading frame 72-amyotrophic lateral sclerosis (C9ORF72-ALS). The secondary objective is to evaluate the pharmacokinectic (PK) of BIIB078 in participants with C9ORF72-ALS.

NCT ID: NCT04248465 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Start date: March 30, 2020
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.

NCT ID: NCT04226144 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Breath Stacking Technique Associated With Expiratory Muscle Training in Amyotrophic Lateral Sclerosis Patients

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

it will be conducted a randomized parallel controlled trial with patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) to compare two techniques to lung recruitment and cough augmentation, to assess their effects on pulmonary function, global functionally, swallowing and ability to speech in these population.

NCT ID: NCT03948178 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

REFALS-ES
Start date: June 26, 2019
Phase: Phase 3
Study type: Interventional

This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS. This is an open-label study, so that all eligible subjects that complete the double-blind REFALS study (48-weeks of treatment) will have the opportunity to receive oral levosimendan treatment. The primary objective, in addition to continuing treatment for subjects enrolled in the REFALS study, is to evaluate long-term safety of oral levosimendan in ALS patients. Another important objective is to explore long-term effectiveness of oral levosimendan in the treatment of patients with ALS. This study is open only to patients taking part in the REFALS study.

NCT ID: NCT03836716 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Start date: September 19, 2019
Phase: Phase 3
Study type: Interventional

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial.

NCT ID: NCT03757351 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis

Start date: December 14, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis in a cross-over design

NCT ID: NCT03679975 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

ROSF
Start date: April 4, 2018
Phase: Phase 2
Study type: Interventional

The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis.

NCT ID: NCT03613571 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis

A Study to Evaluate the Safety, Tolerability and Efficacy of ILB in Patients With Amyotrophic Lateral Sclerosis

Start date: August 15, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2a single-centre, open single-arm study in patients with Amyotrophic Lateral Sclerosis (ALS) of intermediate progression rate. Eligible subjects will be administered weekly doses of ILB. A total of 5 subcutaneous (s.c.) doses will be administered at the study clinic. The study consists of 10 visits; One 2-part screening visit, 5 ILB administration visits, and 3 follow-up visits. Each individual patient's study participation will be 4 months, including the screening and follow-up visits. Fifteen patients are planned to be included. The primary objective of the study is to evaluate the safety and tolerability of ILB in patients diagnosed with ALS. ILB is a solution for subcutaneous (s.c.) injection in saline solution. The dose administered will depend on the subject's body weight at the second study visit, prior to the first ILB administration. No formal sample size calculation has been performed for this study. The proposed sample size is considered sufficient in this early phase 2 development to provide adequate information on the patients. Categorical data will be presented as counts and percentages. Continuous data will be summarised using descriptive statistics.

NCT ID: NCT03580616 Terminated - Clinical trials for Amyotrophic Lateral Sclerosis (ALS)

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)

ALS
Start date: October 24, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy